Quince Therapeutics (NASDAQ:QNCX) Earns Buy Rating from Analysts at Brookline Capital Management

Brookline Capital Management began coverage on shares of Quince Therapeutics (NASDAQ:QNCX - Free Report) in a research note issued to investors on Wednesday,Benzinga reports. The brokerage issued a buy rating and a $9.00 price target on the stock.

QNCX has been the subject of a number of other research reports. Maxim Group initiated coverage on shares of Quince Therapeutics in a research report on Thursday, November 7th. They set a "buy" rating and a $6.00 price objective for the company. Rodman & Renshaw began coverage on Quince Therapeutics in a report on Tuesday, October 29th. They set a "buy" rating and a $11.00 target price for the company. EF Hutton Acquisition Co. I raised Quince Therapeutics to a "strong-buy" rating in a report on Tuesday, October 22nd. Finally, RODMAN&RENSHAW upgraded Quince Therapeutics to a "strong-buy" rating in a research note on Tuesday, October 29th. Three investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Quince Therapeutics currently has an average rating of "Buy" and an average target price of $8.67.

Quince Therapeutics Stock Performance

Shares of NASDAQ QNCX traded up $0.01 during trading on Wednesday, reaching $1.85. The stock had a trading volume of 166,300 shares, compared to its average volume of 233,673. The company has a debt-to-equity ratio of 0.33, a quick ratio of 9.53 and a current ratio of 9.53. The stock has a market cap of $81.40 million, a PE ratio of -1.49 and a beta of 0.74. Quince Therapeutics has a one year low of $0.51 and a one year high of $2.45. The firm's 50 day moving average price is $1.55 and its two-hundred day moving average price is $1.01.

Institutional Trading of Quince Therapeutics

An institutional investor recently raised its position in Quince Therapeutics stock. Geode Capital Management LLC lifted its stake in shares of Quince Therapeutics, Inc. (NASDAQ:QNCX - Free Report) by 24.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 339,125 shares of the company's stock after purchasing an additional 66,170 shares during the quarter. Geode Capital Management LLC owned about 0.78% of Quince Therapeutics worth $263,000 at the end of the most recent reporting period. Institutional investors own 30.75% of the company's stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.